When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...

The primary causes of disability and mortality in the US are chronic diseases such as cancer, neurodegenerative disorders, cardiovascular disease, obesity, arthritis, and diabetes. The increase in ...

10x Genomics has begun shipping to customers the first two products powered by its new GEM-X technology architecture—the Chromium GEM-X Single Cell Gene Expression v4 and its GEM-X Single Cell Immune ...

Innovative and cutting-edge technology transforms functional live-cell analysis by enabling precise, flexible, and scalable end-to-end immuno-oncology, antibody, and cell therapy discovery.

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

The Stagljar Lab is a global leader in proteomics and chemical genomics, specializing in unraveling protein-protein interactions of human membrane proteins. Pivotal in cancer and rare genetic diseases ...

Modern day drug discovery is shifting from single end point assays to more complex phenotypic assays that query single cell and population responses to chemicals and genetic manipulation. One such ...

The disposition of antibody-based therapeutics is generally determined by both target-mediated and non-target processes, the latter being an often-overlooked aspect. Target-independent liabilities can ...

Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, today announced a strategic partnership with Promega to expand Addgene’s ...

Tom Congdon (left) is the CEO and Co-Founder of CryoLogyx (Coventry, UK), a University of Warwick (UK) spinout that develops technology for cryopreservation of cell-based assays and novel ...